Diagnosis and therapy of oral squamous cell carcinoma

References

• Rodrigues VC, Moss SM, Tuomainen H. Oral cancer in the UK, to screen or not screen. Oral Oncol.34, 454–465 (1998).
   PubMed Web of Science ®Google Scholar
• Nemeth ZS, Velich N, Bodgan S, Ujpal M, Szabo G, Suba ZS. The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma52, 95–102 (2005).
   PubMedGoogle Scholar
• Smith EM, Ritchie JM, Summersgill KF et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J. Natl Cancer Inst.96, 449–455 (2004).
   PubMed Web of Science ®Google Scholar
• Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther.107, 155–176 (2005).
   PubMed Web of Science ®Google Scholar
• Brinkman BMN, Wong DTW. Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr. Opin. Oncol.18, 228–233 (2006).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Lothaire P, Dequanter D, Cardoso F, Awada A. Molecular profiling of head and neck tumors. Curr. Opin. Oncol.16, 211–214 (2004).
   PubMedGoogle Scholar
• Sudbo J, Reith A. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int. J. Cancer115, 339–345 (2005).
   PubMed Web of Science ®Google Scholar
• Patmore HS, Cawkwell L, Stafford ND, Greenman J. Unraveling the chromosomal aberrations of head and neck squamous cell carcinoma: a review. Ann. Surg. Oncol.12, 831–842 (2005).
   PubMedGoogle Scholar
• Wolff E, Girod S, Liehr T et al. Oral squamous cell carcinomas are characterized by a rather uniform pattern of genomic imbalances detected by comparative genomic hybridization. Oral Oncol.34, 186–190 (1998).
   PubMedGoogle Scholar
• Liehr T, Ries J, Wolff E et al. Gain of DNA copy number on chromosomes 3q26-qter and 5p14-pter is a frequent finding in head and neck squamous cell carcinomas. Int. J. Mol. Med.2, 173–179 (1998).
   PubMedGoogle Scholar
• Gebhart E, Ries J, Wiltfang J, Liehr T, Efferth T. Genomic gain of the epidermal factor receptor harboring band 7p12 is part of a complex pattern of genomic imbalances in oral squamous cell carcinomas. Arch. Med. Res.34, 385–394 (2004).
   Google Scholar
• Huang Q, Yu GP, McCormick SA et al. Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites, construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer34, 224–233 (2002).
   PubMedGoogle Scholar
• Ashman JNE, Patmore HS, Condon LT, Cawkwell L, Stafford ND, Greenman J. Prognostic value of genomic alteration in head and neck squamous cell carcinoma detected by comparative genomic hybridization. Br. J. Cancer89, 864–869 (2003).
   PubMed Web of Science ®Google Scholar
• Gebhart E, Liehr T, Wolff E et al. Pattern of genomic imbalances in oral squamous cell carcinomas with and without increased copy number of 11q13. Int. J. Oncol.12, 1151–1155 (1998).
   PubMedGoogle Scholar
• Santini J, Formento JL, Francoual M et al. Characterization, quantification, and potential clinical value of epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck13, 132–139 (1991).
   PubMed Web of Science ®Google Scholar
• Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx29, 175–181 (2002).
   PubMed Web of Science ®Google Scholar
• Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck23, 147–159 (2001).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA et al. Epidermal growth factor receptor in non-small-cell lung carcinomas, correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol.21, 3798–3807 (2003).
   PubMed Web of Science ®Google Scholar
• Navolanic PM, Steelman LS, McCubrey JA. EGFR signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol.22, 237–252 (2003).
   PubMed Web of Science ®Google Scholar
• Efferth T, Verdorfer I, Miyachi H et al. Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. Blood Cells Mol. Dis.29, 1–13 (2002).
   PubMed Web of Science ®Google Scholar
• Efferth T, Miyachi H, Drexler HG, Gebhart E. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. Blood Cells Mol. Dis.28, 47–56 (2002).
   PubMed Web of Science ®Google Scholar
• Arteaga CL. Epidermal growth factor receptor dependence in human tumors, more than just expression? Oncologist7(4), 31–39 (2002).
   PubMed Web of Science ®Google Scholar
• Efferth T, Volm M. Antibody-directed therapy of multidrug-resistant tumor cells. Med. Oncol. Tumor Pharmacother.9, 11–19 (1992).
   PubMedGoogle Scholar
• Volm M, Efferth T, Mattern J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. AntiCancer Res.12, 11–20 (1992).
   PubMed Web of Science ®Google Scholar
• Volm M, Kästel M, Mattern J, Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer71, 3981–3987 (1993).
   PubMed Web of Science ®Google Scholar
• Efferth T, Sauerbrey A, Halatsch ME, Ross DD, Gebhart E. Molecular modes of action of cephalotaxine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch. Pharmacol.367, 56–67 (2003).
   PubMed Web of Science ®Google Scholar
• Efferth T, Sauerbrey A, Olbrich A et al. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol.64, 382–394 (2003).
   PubMed Web of Science ®Google Scholar
• Efferth T, Ramirez T, Gebhart E, Halatsch ME. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol.67, 1689–1700 (2004).
   PubMed Web of Science ®Google Scholar
• Barrett-Lee PJ. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies, a review of chemotherapy. Endocr. Relat. Cancer12, S125–S133 (2005).
   PubMedGoogle Scholar
• Press MF, Pike MC, Hung G et al. Amplification and overexpression of Her-2/neu in carcinomas of the salivary gland, correlation with poor prognosis. Cancer Res.54, 5675–5682 (1994).
   PubMed Web of Science ®Google Scholar
• Xia W, Lau YK, Zhang HZ et al. Strong correlation between c-erbB-2 expression and overall survival of patients with oral squamous cell carcinoma. Clin. Cancer Res.3, 3–9 (1997).
   PubMed Web of Science ®Google Scholar
• Venkatesan TK, Kuropkat C, Caldarelli DD et al. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope109, 1329–1333 (1999).
   PubMedGoogle Scholar
• Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J. Oral Pathol. Med.29, 413–425 (2000).
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Kapranos N, Manolopoulos L, Papadimitriou C, Adamopoulos G. Topoisomerase II α expression in squamous cell carcinomas of the head and neck. AntiCancer Res.20, 177–182 (2000).
   PubMedGoogle Scholar
• Georgiou A, Gomatos IP, Ferekidis Eet al. Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. Eur. J. Surg. Oncol.27, 574–580 (2001).
   PubMedGoogle Scholar
• Kapranos N, Stathopoulos GP, Manolopoulos L et al. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. AntiCancer Res.21, 521–528 (2001).
   PubMedGoogle Scholar
• Bandoh H, Hayashi T, Kishibe K et al. Prognostic value of p53 mutations, BAX, and spontaneous apoptosis in maxillary sinus squamous cell carcinomas. Cancer94, 1968–1980 (2002).
   PubMed Web of Science ®Google Scholar
• Couture C, Raybaud-Diogene H, Tetu B et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer94, 713–722 (2002).
   PubMedGoogle Scholar
• Kuropkat C, Venkatesan TK, Caldarelli DD et al. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx29, 165–174 (2002).
   PubMedGoogle Scholar
• Masuda M, Suzui M, Yasumatu R et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res.62, 3351–3355 (2002).
   PubMed Web of Science ®Google Scholar
• Xie X, Clausen OP, Boysen M. Prognostic significance of p21WAF1/CIP1 expression in tongue squamous cell carcinomas. Arch. Otolaryngol. Head Neck Surg.128, 897–902 (2002).
   PubMedGoogle Scholar
• Lemaire F, Millon R, Young J et al. Differential expression profiling of head and neck squamous cell carcinoma (HNSCC). Br. J. Cancer89, 1940–1949 (2003).
   PubMed Web of Science ®Google Scholar
• Logullo AF, Nonogaki S, Miguel RE et al. Transforming growth factor 1 (TGF1) expression in head and neck squamous cell carcinoma patients as related to prognosis. J. Oral Pathol. Med.32, 139–145 (2003).
   PubMed Web of Science ®Google Scholar
• Miyamoto R, Uzawa N, Nagaoka S, Hirata Y, Amagasa T. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol.39, 610–618 (2003).
   PubMed Web of Science ®Google Scholar
• Nguyen DC, Parsa B, Close A, Magnusson B, Sinha UK. Overexpression of cell cycle regulatory proteins correlates with advanced tumor stage in head and neck squamous cell carcinomas. Int. J. Oncol.22, 1285–1290 (2003).
   PubMedGoogle Scholar
• Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin. Cancer Res.10, S4227–S4232 (2004).
   PubMed Web of Science ®Google Scholar
• Oliveira S, van Bergen en Henegouwen PM, Storm G, Schiffelers RM. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin. Biol. Ther.6, 605–617 (2006).
   PubMed Web of Science ®Google Scholar
• Astsaturov I, Cohen R, Harari P. Targeting epidermal growth factor receptor signalling in the treatment of head and neck cancer. Expert Rev. Anticancer Ther.6, 1179–1193 (2006).
   PubMed Web of Science ®Google Scholar
• Perea S, Hidalgo M. Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. Clin. Lung Cancer6, S30–S34 (2004).
   Google Scholar
• Bishop PC, Myers T, Robey R et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene21, 119–127 (2002).
   PubMedGoogle Scholar
• Zhu L, Xu X. Selective separation of active inhibitors of epidermal growth factor receptor from Caragana jubata by molecularly imprinted solid-phase extraction. J. Chromatogr. A991, 151–158 (2003).
   PubMed Web of Science ®Google Scholar
• Lee CS, deFazio A, Ormandy CJ, Sutherland RL. Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester. J. Steroid Biochem. Mol. Biol.58, 267–275 (1996).
   PubMedGoogle Scholar
• Vinod PK, Konkimalla B, Chandra N. In-silico pharmacodynamics, correlation of adverse effects of h(2)-antihistamines with histamine N-methyl transferase binding potential. Appl. Bioinformatics5, 141–150 (2006).
   PubMedGoogle Scholar
• Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands, applications of AutoDock. J. Mol. Recognit.9, 1–5 (1996).
   PubMed Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking, current status and future challenges. Proteins65, 15–26 (2006).
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem.277, 46265–46272 (2002).
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib), relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res.64, 6652–6659 (2004).
   PubMed Web of Science ®Google Scholar
• Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M. Automated analysis of interatomic contacts in proteins. Bioinformatics15, 327–332 (1999).
   PubMed Web of Science ®Google Scholar
• Teng CM, Yu SM, Ko FN, Chen CC, Huang YL, Huang TF. Dicentrine, a natural vascular α 1-adrenoceptor antagonist, isolated from Lindera megaphylla. Br. J. Pharmacol.104, 651–656 (1991).
   PubMedGoogle Scholar
• Kondo Y, Imai Y, Hojo H, Endo T, Nozoe S. Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine, and apomorphine. J. Pharmacobiodyn.13, 426–431 (1990).
   PubMedGoogle Scholar
• Huang RL, Chen CC, Huang YL et al. Anti-tumor effects of d-dicentrine from the root of Lindera megaphylla. Planta Med.64, 212–215 (1998).
   PubMedGoogle Scholar
• Volm M, Koomägi R, Efferth T. Prediction of drug sensitivity and resistance of cancer by protein expression profiling. Cancer Genomics Proteomics1, 157–166 (2004).
   PubMedGoogle Scholar
• Efferth T, Rücker G, Falkenberg M et al. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung46, 196–200 (1996).
   PubMedGoogle Scholar
• Efferth T, Olbrich A, Sauerbrey A, Ross DD, Gebhart E, Neugebauer M. Activity of ascaridol from the anthelmintic herb Chenopodium anthelminticum L. against sensitive and multidrug-resistant tumor cells. Anticancer Res.22, 4221–4224 (2002).
   PubMed Web of Science ®Google Scholar
• Efferth T, Olbrich, A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol.64, 617–623 (2002).
   PubMed Web of Science ®Google Scholar
• Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukaemia cells. Blood Cells Mol. Dis.28, 160–168 (2002).
   PubMed Web of Science ®Google Scholar
• Efferth T, Kaina B. Microarray-based prediction of cytotoxicity of tumor cells to arsenic trioxide. Cancer Genomics Proteomics1, 363–370 (2004).
   PubMedGoogle Scholar
• Rinner B, Siegl V, Purstner P. Activity of novel plant extracts against medullary thyroid carcinoma cells. Anticancer Res.24, 495–500 (2004).
   PubMed Web of Science ®Google Scholar
• Efferth T, Chen Z, Kaina B, Wang G. Molecular determinants of response of tumor cells to berberine. Cancer Genomics Proteomics2, 115–124 (2005).
   Google Scholar
• Efferth T, Rauh R, Kahl S et al. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol.69, 811–818 (2005).
   PubMed Web of Science ®Google Scholar
• Efferth T. Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncol. Rep.13, 459–463 (2005).
   PubMedGoogle Scholar
• Wang J, Zheng Y, Efferth T, Wang R, Shen Y, Hao X. Indole and carbazole alkaloids from Glycosmis montana with weak anti-HIV and cytotoxic activities. Phytochemistry66, 697–701 (2005).
   PubMed Web of Science ®Google Scholar
• Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat.8, 85–97 (2005).
   PubMed Web of Science ®Google Scholar
• Adams M, Efferth T, Bauer R. Activity-guided isolation of scopoletin and isoscopoletin, the inhibitory active principles towards CCRF-CEM leukaemia cells and multi-drug resistant CEM/ADR5000 cells, from Artemisia argyi. Planta Med.72, 862–864 (2006).
   PubMedGoogle Scholar
• Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets7, 407–421 (2006).
   PubMed Web of Science ®Google Scholar
• Fu YJ, Zu Y, Liu W et al. Optimization of luteolin separation from pigeonpea [Cajanus Cajan (L.) Millsp.] leaves by macroporous resins. J. Chromatogr. A1137, 145–152 (2006).
   PubMed Web of Science ®Google Scholar
• Wang YF, Cao YX, Efferth T, Lai GF, Luo SD. Cytotoxic and new tetralone derivatives from Berchemia floribunda (Wall.) Brongn. Chemistry Biodivers.3, 1023–1030 (2006).
   PubMedGoogle Scholar